|
THIS WEEK IN DERMATOLOGY
Scioderm Inc. has released data from its recently completed Phase 2b clinical trial—and plans for a Phase 3 trial—on Zorblisa, a topical treatment for blistering and lesions associated with epidermolysis bullosa (EB). » Market impact could be significant |
ADVERTISEMENT
Electronic brachytherapy for nonmelanoma skin cancer
Electronic brachytherapy promises better continuity of care. But which patients should you refer? How do you coordinate with an oncologist? Find out in a complimentary, 1-hour webinar.
 Click Here.
|
|
Bellafill (Suneva Medical) is the first dermal filler to win the Food and Drug Administration's approval for the treatment of acne scars. » Background data |
|
According to researchers, abnormalities in the skin barrier and in the immune system that characterize atopic dermatitis can be reversed by drugs that narrowly target the immune signaling proteins interleukin (IL)-4 and -13. » Molecular mechanisms behind AD
|
|
|
Like
Tweet
